 The current study is designed as a prospective placebo-controlled trial to investigate the safety and efficacy of a lower dose of dalfampridine extended release tablets 5 mg twice daily compared to the approved commercial dose of 10 mg twice daily in improving walking in MS patients during a four-week period of treatment. 